| | | | | | | | | | | | | | | | |
| |
 | Issue Date FY: 2025 ( Subtotal = $30,832,912 ) (Continued on the next page) |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | K99CA304508 | Mechanisms of dormant breast cancer cell communication with their environment | 000 | 1 | NIH | 7/17/2025 | $123,182 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259046 | Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | 001 | 5 | NIH | 5/5/2025 | $0 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259046 | Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | 002 | 5 | NIH | 5/22/2025 | $41,694 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259046 | Chromosome 1q ceRNAs in Melanoma Progression and Metastasis | 000 | 5 | NIH | 3/20/2025 | $375,244 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279713 | RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing | 001 | 3 | NIH | 6/17/2025 | $46,111 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279713 | RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing | 000 | 3 | NIH | 3/20/2025 | $414,990 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA280404 | Investigating lipid phenotype as a metabolic adaptation to microenvironmental stress | 000 | 2 | NIH | 2/14/2025 | $84,250 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 001 | 3 | NIH | 5/22/2025 | $52,200 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA278300 | The impact of inflammation on HSPC composition and disease progression in chronic myelomonocytic leukemia | 000 | 3 | NIH | 2/14/2025 | $469,813 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA288927 | Development of bifunctional CDK2 inhibitors for treatment of CCNE1-driven cancers | 001 | 2 | NIH | 5/22/2025 | $19,692 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R21CA288927 | Development of bifunctional CDK2 inhibitors for treatment of CCNE1-driven cancers | 000 | 2 | NIH | 3/3/2025 | $177,242 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 001 | 3 | NIH | 6/23/2025 | $53,438 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA269721 | Role of ULK3 in Sensitive and Refractory Multiple Myeloma | 000 | 3 | NIH | 11/15/2024 | $480,943 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | U01DE033329 | Biomarker Approach to Screening for the early detection of HPV-related Oropharyngeal Cancer (BASH OPC) | 001 | 3 | NIH | 6/27/2025 | $715,985 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R37CA276939 | Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma | 000 | 2 | NIH | 7/3/2025 | $507,197 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 001 | 3 | NIH | 6/16/2025 | $59,638 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA275974 | Methylomic basis of survival disparities among Black and White women with high-grade serous ovarian cancer | 000 | 3 | NIH | 12/18/2024 | $536,745 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM155298 | Dissecting enhancer function through integrative genomics | 000 | 2 | NIH | 7/28/2025 | $421,250 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA291735 | A hybrid effectiveness-implementation trial to integrate precision skin cancer risk feedback in federally qualified health centers | 001 | 2 | NIH | 8/5/2025 | $675,011 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P30CA076292 | Moffitt Cancer Center Support Grant | 001 | 27 | NIH | 3/5/2025 | $3,649,340 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01NS135220 | Targeting Malignant Reprogramming of Glioblastoma Stem Cells Through Dual Inhibition of S6K1 and BIRC3 | 000 | 2 | NIH | 12/12/2024 | $541,074 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA287666 | Impact of Targeted Therapy on Cancer-Related Cognitive Impairment | 000 | 2 | NIH | 7/24/2025 | $664,612 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA292692 | Interrogating the relationship between translational dynamics and non-canonical antigen presentation in lung cancer | 000 | 2 | NIH | 6/26/2025 | $485,494 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R03CA286682 | Targeting ULK3 for the treatment of triple negative breast cancer | 000 | 2 | NIH | 11/14/2024 | $84,250 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA280116 | MYC-alarmin axis as a novel therapeutic vulnerability in myelofibrosis | 000 | 2 | NIH | 5/12/2025 | $553,041 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 001 | 2 | NIH | 6/4/2025 | $63,562 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA279378 | Selective targeting of TAF1 function in acute myeloid leukemia | 000 | 2 | NIH | 1/14/2025 | $572,062 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM143004 | Biophysical basis for enzyme mediated deglycation in protein repair | 001 | 5 | NIH | 8/8/2025 | $41,175 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM143004 | Biophysical basis for enzyme mediated deglycation in protein repair | 000 | 5 | NIH | 3/21/2025 | $370,575 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01HL163820 | A redox-sensitive switch in the macrophage nucleus regulates acute phaseinflammatory injury | 001 | 4 | NIH | 7/23/2025 | $613,814 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DA055298 | Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation | 000 | 4 | NIH | 5/16/2025 | $759,650 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262483 | Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma | 000 | 4 | NIH | 6/25/2025 | $485,968 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA256193 | Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis | 000 | 5 | NIH | 8/11/2025 | $651,147 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA255398 | Characterizing oncogenic function of ITCH in melanoma | 000 | 5 | NIH | 7/1/2025 | $357,913 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | P01CA250984 | Identifying Metabolic Vulnerabilities in Lung Cancer | 000 | 5 | NIH | 6/25/2025 | $2,032,950 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262121 | Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds | 000 | 5 | NIH | 7/16/2025 | $376,751 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 001 | 5 | NIH | 5/22/2025 | $44,459 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA260356 | Anti-tumor potential of temperature-sensitive p53 mutants | 000 | 5 | NIH | 2/13/2025 | $400,132 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 001 | 5 | NIH | 5/22/2025 | $47,602 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA259387 | Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer | 000 | 5 | NIH | 3/13/2025 | $428,435 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01DE030123 | Role of CRTC1-MAML2 in Salivary Mucoepidermoid Carcinoma Pathobiology | 001 | 6 | NIH | 5/1/2025 | $498,468 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA262530 | Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers | 000 | 5 | NIH | 6/26/2025 | $681,912 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA253219 | Determining the structural- and functional-level effects of diet-specific interventions on the gut microbiota of a diverse sample of Southern United States adults | 000 | 6 | NIH | 5/23/2025 | $319,019 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R01CA299480 | The MIND-BC Study: MIND diet for Breast cancer Cognition | 000 | 1 | NIH | 3/7/2025 | $713,235 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R34CA297368 | Libre Del Cigarrillo: Development of an mHealth Smoking Cessation App to Extend Reach of a Validated Smoking Cessation Intervention for Spanish-speaking Smokers | 000 | 1 | NIH | 4/1/2025 | $316,873 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 003 | 6 | NIH | 3/6/2025 | $3,083 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 003 | 6 | NIH | 3/6/2025 | $58,549 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | R35GM133482 | Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering | 000 | 6 | NIH | 1/16/2025 | $463,375 |
| 2025 | 2025 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. | 12902 USF MAGNOLIA DR | TAMPA | FL | 33612-9416 | HILLSBOROUGH | USA | UG1HL108987 | Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1 | 002 | 15 | NIH | 7/29/2025 | $214,179 |
|